journal article·2014-01-02

Validation of a Computational Cocrystal Prediction Tool: Comparison of Virtual and Experimental Cocrystal Screening Results

Tudor Grecu, Christopher A. Hunter, Eleanor J. Gardiner, James F. McCabe

Crystal Growth & Design· Volume 14· Issue 1
Publisher page

Abstract

A virtual cocrystal screening method based on calculated gas phase molecular electrostatic potential surfaces (MEPS) of the individual components has been validated using experimental cocrystal screens reported in the literature. The noncovalent interactions of a molecule with its environment are described by a discrete set of independent surface site interaction points (SSIPs), whose properties can be calculated from the ab initio MEPS. The stability of a crystal is estimated based on pairing SSIPs such that the sum of the pairwise interaction energies is optimized. This provides a means of calculating the relative stability of a cocrystal compared with the pure components without knowing anything about the three-dimensional structures of the crystalline states. For a set of potential crystal coformers (CCF), the difference between interaction site pairing energies of different solid forms (Δ E ) provides a method for ranking CCFs based on the calculated probability of cocrystal formation. The method was applied to cocrystal screens of 18 compounds that reported both hits and misses, and in most cases, the virtual cocrystal screen reproduces experimental results well. In lists of CCFs ranked by Δ E, the experimentally observed hits were significantly enriched at the top, and this indicates that virtual screening is a promising tool for focusing experimental efforts on the most promising CCF candidates.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · Chemical Thermodynamics and Molecular Structure

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, University of Sheffield, Sheffield S3 7HF U.K.

Information School, University of Sheffield, Sheffield S4 1DP U.K.

AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA U.K.

References (54)

Show source-provided references
1. Vishweshwar P. · J. Pharm. Sci. · 2006 · 95 · 49910.1002/jps.20578 ↗
2. Shan N. · Drug Discovery Today · 2008 · 13 · 44010.1016/j.drudis.2008.03.004 ↗
3. aBond, A. D.InPharmaceutical Salts and Co-crystals;Wouters, J.; Quéré, L., Eds.RSC Publishing:Cambridge, U.K., 2011; pp9–28.
4. Bond A. D. · CrystEngComm · 2007 · 9 · 83310.1039/b708112j ↗
5. Tiekink E. R. · 2006
6. Aakeröy C. B. · CrystEngComm · 2005 · 7 · 43910.1039/b505883j ↗
7. Babu N. J. · Cryst. Growth Des. · 2011 · 11 · 266210.1021/cg200492w ↗
8. Rodríguez-Hornedo N. · Mol. Pharmaceutics · 2007 · 4 · 29910.1021/mp070042v ↗
9. Almarsson Ö. · Chem. Commun. · 2004 · 188910.1039/b402150a ↗
10. Childs S. L. · J. Am. Chem. Soc. · 2004 · 126 · 1333510.1021/ja048114o ↗
11. Variankaval N. · Cryst. Growth Des. · 2006 · 6 · 69010.1021/cg050462u ↗
12. Li Z. · Org. Process Res. Dev. · 2009 · 13 · 130710.1021/op900137j ↗
13. Leyssens T. · Cryst. Growth Des. · 2012 · 12 · 152010.1021/cg201581z ↗
14. Fleischman S. G. · Cryst. Growth Des. · 2003 · 3 · 90910.1021/cg034035x ↗
15. Remenar J. F. · J. Am. Chem. Soc. · 2003 · 125 · 845610.1021/ja035776p ↗
16. Morissette S. L. · Adv. Drug Delivery Rev. · 2004 · 56 · 27510.1016/j.addr.2003.10.020 ↗
17. Childs S. L. · Cryst. Growth Des. · 2007 · 7 · 129110.1021/cg060742p ↗
18. Kojima T. · Int. J. Pharm. · 2010 · 399 · 5210.1016/j.ijpharm.2010.07.055 ↗
19. Thakur T. S. · Cryst. Growth Des. · 2008 · 8 · 403110.1021/cg800371j ↗
20. bLászló, F.; Friščić, T.InPharmaceutical Salts and Co-crystals;Wouters, J.; Quéré, L., Eds.RSC Publishing:Cambridge, U.K., 2011; pp89–109.
21. Issa N. · Cryst. Growth Des. · 2008 · 9 · 44210.1021/cg800685z ↗
22. Issa N. · CrystEngComm · 2012 · 14 · 245410.1039/c2ce06325e ↗
23. Chan H. S. · CrystEngComm · 2013 · 15 · 379910.1039/c3ce40107c ↗
24. Cruz-Cabeza A. J. · Chem.—Eur. J. · 2008 · 14 · 883010.1002/chem.200800668 ↗
25. Hunter C. A. · Angew. Chem., Int. Ed. · 2004 · 43 · 531010.1002/anie.200301739 ↗
26. Hunter C. A. · Chem. Sci. · 2013 · 4 · 168710.1039/c3sc22124e ↗
27. Calero C. S. · Phys. Chem. Chem. Phys. · 2013 · 15 · 1826210.1039/c3cp53158a ↗
28. Cook J. L. · Angew. Chem., Int. Ed. · 2007 · 46 · 370610.1002/anie.200604966 ↗
29. Musumeci D. · Chem. Sci. · 2011 · 2 · 88310.1039/c0sc00555j ↗
30. Etter M. C. · Acc. Chem. Res. · 1990 · 23 · 12010.1021/ar00172a005 ↗
31. Etter M. C. · J. Phys. Chem. · 1991 · 95 · 460110.1021/j100165a007 ↗
32. US Food and Drug Administration approved GRAS list.http://www.fda.gov/food/ingredientspackaginglabeling/gras/default.htm.
33. Basavoju S. · Pharm. Res. · 2008 · 25 · 53010.1007/s11095-007-9394-1 ↗
34. Aakeröy C. B. · Pharmaceutics · 2011 · 3 · 60110.3390/pharmaceutics3030601 ↗
35. Arenas-García J. I. · Cryst. Growth Des. · 2010 · 10 · 373210.1021/cg1005693 ↗
36. dLynch, D.Private communication to the Cambridge Structural Database, version 5.32 2009.
37. Viertelhaus M. · Cryst. Growth Des. · 2009 · 9 · 222010.1021/cg800942n ↗
38. Mohammad M. A. · J. Pharm. Pharmacol. · 2010 · 62 · 1360
39. Goud N. R. · J. Pharm. Sci. · 2012 · 101 · 66410.1002/jps.22805 ↗
40. Báthori N. B. · Cryst. Growth Des. · 2011 · 11 · 7510.1021/cg100670k ↗
41. Umeda Y. · Drug Dev. Ind. Pharm. · 2009 · 35 · 84310.1080/03639040802660489 ↗
42. Adalder T. K. · Cryst. Growth Des. · 2012 · 12 · 253310.1021/cg300140w ↗
43. http://www.cresset-group.com/products/torch/torchlite/
44. Childs S. L. · Mol. Pharmaceutics · 2007 · 4 · 32310.1021/mp0601345 ↗
45. Arenas-García J. I. · Cryst. Growth Des. · 2010 · 10 · 373210.1021/cg1005693 ↗
46. Abramov Y. A. · J. Pharm. Sci. · 2012 · 101 · 368710.1002/jps.23227 ↗
47. Remenar J. F. · J. Am. Chem. Soc. · 2003 · 125 · 845610.1021/ja035776p ↗
48. Bis J. A. · Mol. Pharmaceutics · 2007 · 4 · 40110.1021/mp070012s ↗
49. Berry D. J. · Cryst. Growth Des. · 2008 · 8 · 169710.1021/cg800035w ↗
50. Karki S. · Adv. Mater. · 2009 · 21 · 390510.1002/adma.200900533 ↗
51. Cheney M. L. · Cryst. Growth Des. · 2010 · 10 · 440110.1021/cg100514g ↗
52. Seaton C. C. · Cryst. Growth Des. · 2011 · 11 · 150210.1021/cg101403j ↗
53. Mohammad M. A. · Int. J. Pharm. · 2011 · 407 · 6310.1016/j.ijpharm.2011.01.030 ↗
54. Kojima T. · Int. J. Pharm. · 2010 · 399 · 5210.1016/j.ijpharm.2010.07.055 ↗